5 research outputs found
Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer’s Disease
The main hallmarks of Alzheimer’s disease (AD) are extracellular deposits of amyloid plaques and intracellular accumulation of hyperphosphorylated neurofibrillary tangles (tau). However, the mechanisms underlying these neuropathological changes remain largely unclear. To date, plenty of studies have shown that microglia-mediated neuroinflammation contributes to the pathogenesis of AD, and the microglia-synapse pathways have been repeatedly identified as the crucial factor in the disease process. In this review, evidences from microglia and synapse studies are presented, and the role of microglia in the pathogenesis of AD, the contributing factors to synapse dysfunction, and the role and mechanisms of microglia-synapse pathways will be discussed
Identifying circRNA–miRNA–mRNA Regulatory Networks in Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and severe side effect of first-line chemotherapeutic agents. The association between circular RNAs (circRNAs) and CIPN remains unclear. In this study, CIPN models were constructed with Taxol, while 134 differentially expressed circRNAs, 353 differentially expressed long non-coding RNAs, and 86 differentially expressed messenger RNAs (mRNAs) were identified utilizing RNA sequencing. CircRNA-targeted microRNAs (miRNAs) were predicted using miRanda, and miRNA-targeted mRNAs were predicted using TargetScan and miRDB. The intersection of sequencing and mRNA prediction results was selected to establish the circRNA–miRNA–mRNA networks, which include 15 circRNAs, 18 miRNAs, and 11 mRNAs. Functional enrichment pathway analyses and immune infiltration analyses revealed that differentially expressed mRNAs were enriched in the immune system, especially in T cells, monocytes, and macrophages. Cdh1, Satb2, Fas, P2ry2, and Zfhx2 were further identified as hub genes and validated by RT-qPCR, correlating with macrophages, plasmacytoid dendritic cells, and central memory CD4 T cells in CIPN. Additionally, we predicted the associated diseases, 36 potential transcription factors (TFs), and 30 putative drugs for hub genes using the DisGeNET, TRRUST, and DGIdb databases, respectively. Our results indicated the crucial role of circRNAs, and the immune microenvironment played in CIPN, providing novel insights for further research
Roflupram, a Phosphodiesterase 4 Inhibitior, Suppresses Inflammasome Activation through Autophagy in Microglial Cells
Inhibition
of phosphodiesterase 4 (PDE4) suppressed the inflammatory responses
in the brain. However, the underlying mechanisms are poorly understood.
Roflupram (ROF) is a novel PDE4 inhibitor. In the present study, we
found that ROF enhanced the level of microtubule-associated protein
1 light chain 3 II (LC3-II) and decreased p62 in microglial BV-2 cells.
Enhanced fluorescent signals were observed in BV-2 cells treated with
ROF by Lysotracker red and acridine orange staining. In addition,
immunofluorescence indicated a significant increase in punctate LC3.
Moreover, β amyloid 25–35 (Aβ<sub>25–35</sub>) or lipopolysaccharide (LPS) with ATP was used to activate inflammasome.
We found that both LPS plus ATP and Aβ<sub>25–35</sub> enhanced the conversion of pro-caspase-1 to cleaved-caspase-1 and
increased the production of mature IL-1β in BV-2 cells. Interestingly,
these effects were blocked by the treatment of ROF. Consistently,
knocking down the expression of PDE4B in primary microglial cells
led to enhanced level of LC-3 II and decreased activation of inflammasome.
What’s more, Hoechst staining showed that ROF decreased the
apoptosis of neuronal N2a cells in conditioned media from microglia.
Our data also showed that ROF dose-dependently enhanced autophagy,
reduced the activation of inflammasome and suppressed the production
of IL-1β in mice injected with LPS. These effects were reversed
by inhibition of microglial autophagy. These results put together
demonstrate that ROF inhibits inflammasome activities and reduces
the release of IL-1β by inducing autophagy. Therefore, ROF could
be used as a potential therapeutic compound for the intervention of
inflammation-associated diseases in the brain